Development of new predictive markers for endocrine therapy and resistance in breast cancer

Katrine L Henriksen; Katrine Sonne-Hansen; Tove Kirkegaard; Thomas Frogne; Anne E Lykkesfeldt

doi:10.1080/02841860802026993

Development of new predictive markers for endocrine therapy and resistance in breast cancer

Katrine L Henriksen, Katrine Sonne-Hansen, Tove Kirkegaard, Thomas Frogne, Anne E Lykkesfeldt

6 Citations (Scopus)

Abstract

Today, the decision to treat breast cancer patients with endocrine therapy relies solely on tumor expression of two predictive factors, the estrogen receptor and the progesterone receptor. Expression of these hormone receptors are, however, not a guarantee for a response to treatment and patients who experience response at first may become resistant after prolonged treatment. This paper describes the use of preclinical models to identify mechanisms and new markers for endocrine sensitivity and resistance and the translation of these data to clinical utility.

Original language	English
Journal	Acta oncologica (Stockholm, Sweden)
Volume	47
Issue number	4
Pages (from-to)	795-801
Number of pages	7
DOIs	https://doi.org/10.1080/02841860802026993
Publication status	Published - 2008
Externally published	Yes

Keywords

Aromatase Inhibitors
Breast Neoplasms
Estrogen Receptor Modulators
Female
Humans
Tumor Markers, Biological

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/02841860802026993

Cite this

@article{d4a9c873378a40d29b0a3471017f8e55,

title = "Development of new predictive markers for endocrine therapy and resistance in breast cancer",

abstract = "Today, the decision to treat breast cancer patients with endocrine therapy relies solely on tumor expression of two predictive factors, the estrogen receptor and the progesterone receptor. Expression of these hormone receptors are, however, not a guarantee for a response to treatment and patients who experience response at first may become resistant after prolonged treatment. This paper describes the use of preclinical models to identify mechanisms and new markers for endocrine sensitivity and resistance and the translation of these data to clinical utility.",

keywords = "Aromatase Inhibitors, Breast Neoplasms, Estrogen Receptor Modulators, Female, Humans, Tumor Markers, Biological",

author = "Henriksen, {Katrine L} and Katrine Sonne-Hansen and Tove Kirkegaard and Thomas Frogne and Lykkesfeldt, {Anne E}",

year = "2008",

doi = "10.1080/02841860802026993",

language = "English",

volume = "47",

pages = "795--801",

journal = "Acta oncologica (Stockholm, Sweden)",

issn = "1502-3850",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Development of new predictive markers for endocrine therapy and resistance in breast cancer

AU - Henriksen, Katrine L

AU - Sonne-Hansen, Katrine

AU - Kirkegaard, Tove

AU - Frogne, Thomas

AU - Lykkesfeldt, Anne E

PY - 2008

Y1 - 2008

N2 - Today, the decision to treat breast cancer patients with endocrine therapy relies solely on tumor expression of two predictive factors, the estrogen receptor and the progesterone receptor. Expression of these hormone receptors are, however, not a guarantee for a response to treatment and patients who experience response at first may become resistant after prolonged treatment. This paper describes the use of preclinical models to identify mechanisms and new markers for endocrine sensitivity and resistance and the translation of these data to clinical utility.

AB - Today, the decision to treat breast cancer patients with endocrine therapy relies solely on tumor expression of two predictive factors, the estrogen receptor and the progesterone receptor. Expression of these hormone receptors are, however, not a guarantee for a response to treatment and patients who experience response at first may become resistant after prolonged treatment. This paper describes the use of preclinical models to identify mechanisms and new markers for endocrine sensitivity and resistance and the translation of these data to clinical utility.

KW - Aromatase Inhibitors

KW - Breast Neoplasms

KW - Estrogen Receptor Modulators

KW - Female

KW - Humans

KW - Tumor Markers, Biological

U2 - 10.1080/02841860802026993

DO - 10.1080/02841860802026993

M3 - Journal article

C2 - 18465351

SN - 1502-3850

VL - 47

SP - 795

EP - 801

JO - Acta oncologica (Stockholm, Sweden)

JF - Acta oncologica (Stockholm, Sweden)

IS - 4

ER -

Development of new predictive markers for endocrine therapy and resistance in breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this